Related Experiment Video
Updated: Nov 14, 2025

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
Published on: June 16, 2023
Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?
1Department of Pharmaceutical Sciences and Center for Blood Brain Barrier Research, School of Pharmacy, TTUHSC, Amarillo, TX, USA.
Insights
A "vasoactive peptide storm" involving bradykinin, substance P, and neurotensin may drive severe COVID-19 complications. Targeting these peptides simultaneously could offer better therapeutic benefits than single-mechanism treatments for coronavirus disease 2019.
Area of Science:
- Biomedical Science
- Molecular Biology
- Pathophysiology
Background:
- Coronavirus disease 2019 (COVID-19) poses significant global health and economic challenges.
- Inflammation, particularly cytokine storm, is linked to severe COVID-19 complications.
- Bradykinin dysregulation has been recently implicated in COVID-19 severity.
Purpose of the Study:
- To explore molecular mechanisms underlying COVID-19 severity beyond the "cytokine storm" and "bradykinin storm."
- To identify additional vasoactive peptides contributing to COVID-19 pathology.
- To propose a novel therapeutic strategy targeting multiple peptidergic systems.
Main Methods:
- Review of existing scientific literature and experimental observations.
- Analysis of molecular pathways involved in inflammation and microvascular permeability.
- Postulation of the role of specific peptidases in peptide accumulation.
Main Results:
- Evidence suggests substance P and neurotensin, alongside bradykinin, contribute to microvascular permeability and inflammation in COVID-19.
- Neurolysin (Nln) is postulated to play a role in the accumulation of these vasoactive peptides.
- A "vasoactive peptide storm" is proposed as a key driver of COVID-19 pathology.
Conclusions:
- The severity of COVID-19 may be driven by a "vasoactive peptide storm" involving bradykinin, substance P, and neurotensin.
- Simultaneous inhibition of these three peptidergic systems may offer superior therapeutic advantages over targeting a single mechanism.
- This review highlights a potential new avenue for developing effective COVID-19 treatments.
Abstract:
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to be a world-wide pandemic with overwhelming socioeconomic impact. Since inflammation is one of the major causes of COVID-19 complications, the associated molecular mechanisms have been the focus of many studies to better understand this disease and develop improved treatments for patients contracting SARS-CoV-2. Among these, strong emphasis has been placed on pro-inflammatory cytokines, associating severity of COVID-19 with so-called "cytokine storm." More recently, peptide bradykinin, its dysregulated signaling or "bradykinin storm," has emerged as a primary mechanism to explain COVID-19-related complications. Unfortunately, this important development may not fully capture the main molecular players that underlie the disease severity. To this end, in this focused review, several lines of evidence are provided to suggest that in addition to bradykinin, two closely related vasoactive peptides, substance P and neurotensin, are also likely to drive microvascular permeability and inflammation, and be responsible for development of COVID-19 pathology. Furthermore, based on published experimental observations, it is postulated that in addition to ACE and neprilysin, peptidase neurolysin (Nln) is also likely to contribute to accumulation of bradykinin, substance P and neurotensin, and progression of the disease. In conclusion, it is proposed that "vasoactive peptide storm" may underlie severity of COVID-19 and that simultaneous inhibition of all three peptidergic systems could be therapeutically more advantageous rather than modulation of any single mechanism alone.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Heart Failure Drugs: β-Blockers
Antihypertensive Drugs: Action of β1 Blockers
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...

